REGULATORY

Japan Pharma Chief Happy with Direction of Chuikyo Debates on Tax Hike-Linked Price Revision

December 6, 2018
Isao Teshirogi, chairman of the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), on December 5 offered a positive assessment of how discussions are going with regard to an ad hoc drug price revision in 2019 associated with the planned…

To read the full story

REGULATORY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…